- Home
- AES vs RNA Comparison
AES vs RNA Comparison
Compare AES & RNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AES | RNA |
|---|---|---|
| Founded | 1981 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.9B | 10.9B |
| IPO Year | 1991 | 2020 |
Fundamental Metrics
Financial Performance| Metric | AES | RNA |
|---|---|---|
| Price | $16.41 | $72.89 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 10 | 20 |
| Target Price | $15.89 | ★ $69.26 |
| AVG Volume (30 Days) | ★ 10.5M | 1.9M |
| Earning Date | 02-26-2026 | 02-26-2026 |
| Dividend Yield | ★ 4.33% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.46 | N/A |
| Revenue | ★ $12,094,000,000.00 | $20,868,000.00 |
| Revenue This Year | $1.27 | $88.12 |
| Revenue Next Year | $4.33 | $18.11 |
| P/E Ratio | $11.10 | ★ N/A |
| Revenue Growth | N/A | ★ 106.27 |
| 52 Week Low | $9.46 | $21.51 |
| 52 Week High | $16.35 | $73.06 |
Technical Indicators
Market Signals| Indicator | AES | RNA |
|---|---|---|
| Relative Strength Index (RSI) | 68.04 | 66.57 |
| Support Level | $15.81 | $72.80 |
| Resistance Level | $16.19 | $73.06 |
| Average True Range (ATR) | 0.48 | 0.21 |
| MACD | 0.15 | -0.04 |
| Stochastic Oscillator | 93.85 | 73.49 |
Price Performance
Historical ComparisonAbout AES The AES Corporation
AES is a global power company that operates in 15 countries. Its generation portfolio totals over 32 gigawatts, including renewable energy (50%), gas (32%), coal (16%), and oil (2%). AES has majority ownership and operates six electric utilities distributing power to more than 2.5 million customers.
About RNA Avidity Biosciences Inc.
Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.